thiopental Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hypnotics, barbituric acid derivatives 2633 76-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pentothal
  • thiopental sodium
  • thiopental
  • thiomebumal
  • thionembutal
  • pentothiobarbital
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.
  • Molecular weight: 242.34
  • Formula: C11H18N2O2S
  • CLOGP: 2.98
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 58.20
  • ALOGS: -3.78
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.63 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA ABBOTT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 129.96 112.07 37 198 32399 2325451
Exposure during pregnancy 124.81 112.07 34 201 25185 2332665

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 95.45 76.69 18 158 2028 1744577

Pharmacologic Action:

SourceCodeDescription
ATC N01AF03 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Barbiturates, plain
ATC N05CA19 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Barbiturates, plain
MeSH PA D000777 Anesthetics
CHEBI has role CHEBI:88188 drug allergen
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:38877 intravenous anaesthetic
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Benign intracranial hypertension indication 68267002 DOID:11459
Epilepsy indication 84757009 DOID:1826
Narcoanalysis indication 302683009
Cerebral ischemia off-label use 287731003
Hypoxia of brain off-label use 389088001
Chronic disease of respiratory system contraindication 17097001
Shock contraindication 27942005
Myxedema contraindication 43153006 DOID:11634
Uremia contraindication 44730006 DOID:4676
Low blood pressure contraindication 45007003
Variegate porphyria contraindication 58275005 DOID:4346
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Acute disease of cardiovascular system contraindication 128487001
Asthma contraindication 195967001 DOID:2841
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Primary adrenocortical insufficiency contraindication 373662000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.46 acidic
pKa2 11.46 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor; anion channel Ion channel IC50 4.53 CHEMBL
Potassium voltage-gated channel subfamily C member 4 Unclassified GATING INHIBITOR IC50 4 IUPHAR

External reference:

IDSource
4018713 VUID
N0000179744 NUI
C0936073 UMLSCUI
D00714 KEGG_DRUG
49Y44QZL70 UNII
433 INN_ID
71-73-8 SECONDARY_CAS_RN
349829005 SNOMEDCT_US
4019945 VANDF
10493 RXNORM
d00388 MMSL
004578 NDDF
412605006 SNOMEDCT_US
3000715 PUBCHEM_CID
CHEBI:102166 CHEBI
CHEMBL441 ChEMBL_ID
CHEMBL738 ChEMBL_ID
DB00599 DRUGBANK_ID
EDP PDB_CHEM_ID
D013874 MESH_DESCRIPTOR_UI
2579 IUPHAR_LIGAND_ID

Pharmaceutical products:

None